Last reviewed · How we verify
Amoxicillin, Metronidazole
Amoxicillin inhibits bacterial cell wall synthesis while metronidazole disrupts anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic and anaerobic pathogens.
Amoxicillin inhibits bacterial cell wall synthesis while metronidazole disrupts anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic and anaerobic pathogens. Used for Helicobacter pylori infection (as part of triple or quadruple therapy), Polymicrobial infections involving aerobic and anaerobic bacteria, Intra-abdominal infections.
At a glance
| Generic name | Amoxicillin, Metronidazole |
|---|---|
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Beta-lactam antibiotic + nitroimidazole antibiotic combination |
| Target | Penicillin-binding proteins (amoxicillin); anaerobic DNA (metronidazole) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that binds to penicillin-binding proteins and inhibits peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis. Metronidazole is a nitroimidazole that generates reactive intermediates in anaerobic organisms, causing DNA strand breaks and cell death. Together, this combination targets both aerobic gram-positive and gram-negative bacteria as well as anaerobes.
Approved indications
- Helicobacter pylori infection (as part of triple or quadruple therapy)
- Polymicrobial infections involving aerobic and anaerobic bacteria
- Intra-abdominal infections
- Periodontal infections
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Metallic taste (metronidazole)
- Allergic reaction (amoxicillin)
- Headache
Key clinical trials
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
- Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (PHASE4)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp First-line Therapy (PHASE4)
- Fecal Molecular Susceptibility-guided Hp Rescue Therapy (PHASE4)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |